Gland Pharma Q2 FY27 Profit Jumps 58% as CDMO Grows 31%
Gland Pharma Q2 FY27 net profit rises 58% to ₹291 crore as revenue grows 23% to ₹1,834 crore, led by 31% CDMO growth and a 42% jump in US sales.
GLAND-PHARMA
Gland Pharma Wins USFDA Nod for Generic Depo-Medrol Injection
Gland Pharma wins USFDA approval for generic Methylprednisolone Acetate Injectable Suspension, equal to Pfizer’s Depo-Medrol, a USD 214 million US market.
Gland Pharma Secures USFDA Approval for Latanoprost Ophthalmic Solution, Strengthening Global Ophthalmology Portfolio
Gland Pharma Limited, a prominent player in the pharmaceutical industry specializing in generic injectables, has achieved a critical milestone with […]
Gland Pharma, Akshaya Patra Foundation partner to provide 13,000 ‘Happiness Kits’ for Covid-19 Food Relief Effort
Covid 19 has impacted the lives and livelihood of millions of underprivileged daily wagers and migrant labourers in India. To […]
Fosun to buy 74% stake in Gland Pharma
Shanghai Fosun Pharmaceutical Group Co. Ltd, a unit of Chinas Fosun Group has agreed to acquire 74 percent of Indian […]
Dr Reddys Lab, Gland Pharma to market generic injectables globally
Dr Reddys Laboratories and US-based Gland Pharma have collaborated to market and distribute a diverse portfolio of eight injectable Abbreviated […]
